A Retrospective Analysis of the Role of Proton Pump Inhibitors in Colorectal Cancer Disease Survival

Abstract

Background Proton pump inhibitors (ppis) are a commonly used medication. A limited number of studies have

Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis

“…A total of 353 potentially eligible records were identified in the electronic databases. After exclusion of n = 337 not pertinent papers, n = 16 were selected for inclusion in quantitative analysis (n = 372,418 patients included, with 12% of patients receiving concomitant GAS therapy) [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31]. The search results and characteristics of the included studies are presented in Figure 1 and Tables 1 and Table 2.…”

Impact of Use of Gastric-Acid Suppressants and Oral Anticancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis

“…A total of 353 potentially eligible records were identified in the electronic databases. After exclusion of n=337 not pertinent papers, n=16 were selected for inclusion in quantitative analysis (n=372,418 patients included, with 12% of patients receiving concomitant GAS therapy) [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31]. The search results and characteristics of the included studies are presented in figure 1 and tables 1-2.…”

Impact of Use of Gastric-Acid Suppressants and Oral Anticancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis

“…A total of 353 potentially eligible records were identified in the electronic databases. After exclusion of n=337 not pertinent papers, n=16 were selected for inclusion in quantitative analysis (n=372,418 patients included, with 12% of patients receiving concomitant GAS therapy) [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31] All studies were retrospective except for a pooled analysis of phase 2-3 studies by Lalani et al and a secondary analysis of a randomized prospective trial by Chu et al Oncologic treatment consisted in oral TKIs in n=11 studies, while in n=4 studies patients received oral chemotherapy (i.e. capecitabine); one study did not include information regarding the type of study drugs.…”